Skip to main content

Advertisement

SpringerLink
Log in

Incidence and course of Epstein-Barr virus viremia after allogeneic hematopoietic stem cell transplant for adult-onset systemic chronic active Epstein-Barr virus disease

  • Correspondence
  • Published:
Bone Marrow Transplantation Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1: Incidence and course of EBV viremia after allogeneic HSCT for CAEBV.

Data availability

The data that support the findings of this study are available from the corresponding author upon reasonable request.

References

  1. Yamamoto M, Sato M, Onishi Y, Sasahara Y, Sano H, Masuko M, et al. Registry data analysis of hematopoietic stem cell transplantation on systemic chronic active Epstein-Barr virus infection patients in Japan. Am J Hematol. 2022;97:780–90. https://doi.org/10.1002/ajh.26544.

    Article  CAS  PubMed  Google Scholar 

  2. Kimura H, Ito Y, Kawabe S, Gotoh K, Takahashi Y, Kojima S, et al. EBV-associated T/NK-cell lymphoproliferative diseases in nonimmunocompromised hosts: prospective analysis of 108 cases. Blood 2012;119:673–86. https://doi.org/10.1182/blood-2011-10-381921.

    Article  CAS  PubMed  Google Scholar 

  3. Onishi Y, Onodera K, Fukuhara N, Kato H, Ichikawa S, Fujiwara T, et al. Unrelated cord blood transplantation for adult-onset EBV-associated T-cell and NK-cell lymphoproliferative disorders. Int J Hematol. 2022;115:873–81. https://doi.org/10.1007/s12185-022-03313-z.

    Article  CAS  PubMed  Google Scholar 

  4. Arai A, Sakashita C, Hirose C, Imadome KI, Yamamoto M, Jinta M, et al. Hematopoietic stem cell transplantation for adults with EBV-positive T- or NK-cell lymphoproliferative disorders: efficacy and predictive markers. Bone Marrow Transpl. 2016;51:879–82. https://doi.org/10.1038/bmt.2016.3.

    Article  CAS  Google Scholar 

  5. Kawada JI, Kamiya Y, Sawada A, Iwatsuki K, Izutsu K, Torii Y, et al. Viral DNA loads in various blood components of patients with Epstein-Barr virus-positive T-cell/natural killer cell lymphoproliferative diseases. J Infect Dis. 2019;220:1307–11. https://doi.org/10.1093/infdis/jiz315.

    Article  CAS  PubMed  Google Scholar 

  6. Bontems S, Boreux R, Capraro V, Huynen P, Descy J, Melin P, et al. Evaluation of the Abbott RealTime quantitative CMV and EBV assays using the maxCycle protocol in a laboratory automation context. J Virol Methods. 2019;270:137–45. https://doi.org/10.1016/j.jviromet.2019.05.007.

    Article  CAS  PubMed  Google Scholar 

  7. Styczynski J, van der Velden W, Fox CP, Engelhard D, de la Camara R, Cordonnier C, et al. Management of Epstein-Barr Virus infections and post-transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation: Sixth European Conference on Infections in Leukemia (ECIL-6) guidelines. Haematologica. 2016;101:803–11. https://doi.org/10.3324/haematol.2016.144428.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Wei N, Wang Y, Wang J, Wu L, Wang Z. Characteristics of Epstein-Barr virus reactivation after allogeneic haematopoietic stem cell transplantation in patients with chronic active Epstein-Barr virus disease: favorable responses to rituximab. Bone Marrow Transpl. 2021;56:1449–51. https://doi.org/10.1038/s41409-020-01193-7.

    Article  CAS  Google Scholar 

  9. Okuno Y, Murata T, Sato Y, Muramatsu H, Ito Y, Watanabe T, et al. Defective Epstein-Barr virus in chronic active infection and haematological malignancy. Nat Microbiol. 2019;4:404–13. https://doi.org/10.1038/s41564-018-0334-0.

    Article  CAS  PubMed  Google Scholar 

  10. Venturini C, Houldcroft CJ, Lazareva A, Wegner F, Morfopoulou S, Amrolia PJ, et al. Epstein-Barr virus (EBV) deletions as biomarkers of response to treatment of chronic active EBV. Br J Haematol. 2021;195:249–55. https://doi.org/10.1111/bjh.17790.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Kinzel M, Kalra A, Khanolkar RA, Williamson TS, Li N, Khan F, et al. Rituximab toxicity after preemptive or therapeutic administration for post-transplant lymphoproliferative disorder. Transpl Cell Ther. 2023;29:43.e1–43.e8. https://doi.org/10.1016/j.jtct.2022.10.013.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We would like to thank Rhalp Jaylord Valenzuela for his statistical expertise.

Author information

Authors and Affiliations

  1. Department of Hematology, Hokkaido University, Faculty of Medicine, Graduate School of Medicine, Sapporo, Japan

    Preeti Prerna M. Vaswani, Masahiro Onozawa, Yuta Hasegawa, Hiroyuki Ohigashi, Takahide Ara, Toshihiro Matsukawa, Atsushi Yasumoto, Souichi Shiratori, Hideki Goto, Masao Nakagawa, Kaoru Kahata, Tomoyuki Endo, Daigo Hashimoto & Takanori Teshima

  2. Section of Hematology, Division of Internal Medicine, National Kidney and Transplant Institute, Quezon City, Philippines

    Preeti Prerna M. Vaswani

Authors
  1. Preeti Prerna M. Vaswani
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Masahiro Onozawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yuta Hasegawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hiroyuki Ohigashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Takahide Ara
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Toshihiro Matsukawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Atsushi Yasumoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Souichi Shiratori
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Hideki Goto
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Masao Nakagawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Kaoru Kahata
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Tomoyuki Endo
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Daigo Hashimoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Takanori Teshima
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

PPMV and MO designed the research, analyzed the data, and wrote the manuscript. All the authors contributed to data collection and review of the manuscript. All authors approved the final manuscript for publishing.

Corresponding author

Correspondence to Masahiro Onozawa.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Vaswani, P.P.M., Onozawa, M., Hasegawa, Y. et al. Incidence and course of Epstein-Barr virus viremia after allogeneic hematopoietic stem cell transplant for adult-onset systemic chronic active Epstein-Barr virus disease. Bone Marrow Transplant 58, 1397–1399 (2023). https://doi.org/10.1038/s41409-023-02103-3

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41409-023-02103-3

  • Springer Nature Limited

Search

Navigation